Note: Ingredients listed on restricted chemical lists
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
*
General Information
Version
1.2
Revision date
2007-11-14
Product name
Cytarabine Solution for Injection
Product name
Cytarabine Solution for Injection
Identification on the label/Trade name
Cytosar; Aracytine; Ara-C
Chemical name
Mixture
1.2.1 Relevant identified uses
Pharmaceutical product used as Antineoplastic
Emergency telephone
1-800-424-9300, +44 (0)208 762 8322
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
WARNING
Hazard Codes
Hazard statements (CLP)
H341, H361d
Hazard statements
Code
Statements
H341
Suspected of causing genetic defects
Section 2
SECTION 2: Hazards identification
Appearance Colorless solution
Signal word
WARNING
Hazard statements
Suspected of damaging the unborn child. Suspected of causing genetic defects.
Additional information
Short Term May cause eye and skin irritation (based on components) . Long Term Animal studies have shown a potential to cause adverse effects on the fetus. Known Clinical Effects Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects seen in clinical use include gastrointestinal discomfort, dizziness, and headache. EU Indication of danger Toxic to reproduction, Category 2 Mutagenic Category 2 EU Hazard Symbols EU Risk Phrases R46 - May cause heritable genetic damage. R61 - May cause harm to the unborn child. Note This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
